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Description
Abstract. Background/Aim: Individuals negative for
Helicbacter pylori antibody and with a normal pepsinogen test
(group A) are regarded as being at low risk in serum gastric
cancer screening known as the ABC method, and endoscopy
is not recommended; however, this group may include 2-10%
of gastric cancer cases. Patients and Methods: A total of 345
individuals who underwent upper gastrointestinal endoscopy
and were classified by ABC as group A (H. pylori antibody
titer <10 U/ml, and pepsinogen-I >70 ng/ml or I/II ratio >3)
were enrolled, and predictors of gastric neoplasia were
investigated. Results: Ten gastric neoplasia cases (gastric
cancer and adenoma) were found to be included. Multiple
logistic regression analyses identified H. pylori antibody titer
≥3 U/ml (odds ratio=14.4, 95% confidence interval=2.7-76.9;
p<0.01) and pepsinogen-I/II ratio ≤4.3 ng/ml (odds
ratio=10.0, 95% confidence interval=2.1-47.9; p<0.01), but
not age as independent predictive factors of neoplasia.
Conclusion: Endoscopy should be considered in individuals
with H. pylori antibody titer of ≥3 U/ml and a pepsinogen-I/II
ratio of ≤4.3 in those classed as group A by ABC method.
Many epidemiological and experimental studies agree with the
association between gastric carcinogenesis and Helicobacter
pylori infection (1-5). H. pylori-related gastritis extends from
the antrum to the corpus, and results in extensive atrophic
gastritis with intestinal metaplasia, a precursor of non-cardia
gastric cancer (6, 7). There is an general agreement that the
serum pepsinogen level is associated with progression of
atrophic gastritis (8, 9). H. pylori antibody reflects H. pylori
infection status quantitatively; the reported sensitivity for H.
pylori infection is over 90% (10, 11). Thus, the screening
method of the combination of serum pepsinogen and serum H.
pylori antibody titer is advocated for gastric cancer screening,
and is called the “ABC method” (12-14). Several prospective
studies have confirmed that the ABC method provides good
gastric cancer screening (12-15). 
With the ABC method, the risk for the development of gastric
cancer is stratified into four categories: group A: H. pylori-
negative (titer <10 U/ml), normal pepsinogen (pepsinogen-I >70
ng/ml or I/II ratio >3); group B: H. pylori-positive, normal
pepsinogen; group C: H. pylori-positive, abnormal pepsinogen;
and group D: H. pylori-negative, abnormal pepsinogen. The risk
of gastric cancer is the highest in group D, followed in order by
groups C, B, and A (12). However, several investigators have
recently reported that even about 2-10% of gastric cancer cases
were classified into group A, suggesting that a certain
percentage of those in group A are not true H. pylori-negative
cases, and some develop gastric cancer (16-20). Thus, it is
important to identify the patients at high risk for gastric cancer
among those with a normal pepsinogen and negative H. pylori
antibody titer. Recently, several studies have pointed-out the
relationship between the H. pylori antibody titer and gastric
cancer risk, especially in subjects with advanced atrophy (21-
24). However, the risk factors among those at low risk have not
yet been fully elucidated. 
In the present study, the aim was to identify clinically
useful factors associated with gastric neoplasia cases among
individuals negative for serum H. pylori antibody and having
a normal pepsinogen status (group A by the ABC method). 
Patients and Methods
Between 2007 and 2015, a total of 734 outpatients who attended the
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were prospectively enrolled. The reasons for performing endoscopy
were as follows: dyspepsia, annual endoscopic follow-up, screening
purpose in asymptomatic individuals, abnormalities on barium X-
ray examinations, and positive ABC screening method.
A blood sample was drawn before the endoscopic examination.
Measurement of serum pepsinogen-I, pepsinogen-II, and H. pylori
IgG antibodies was contracted out to LSI Medience Co., Ltd.
(Tokyo, Japan), as described previously (24, 25). The criterion of
pepsinogen-I ≤70 ng/ml and pepsinogen-I/II ratio ≤3 has been
widely applied to mass screening for gastric cancer; atrophy-positive
is defined when the criterion is fulfilled, and atrophy-negative is
defined when the criterion is not fulfilled (13, 14, 26, 27). The
reported sensitivity and specificity of these criteria to detect
extensive atrophy is 70.5% and 97%, respectively (27). 
The IgG antibody titer was measured with a direct Enzyme
immunoassay (EIA) kit (E Plate “Eiken” Hp antibody; Eiken Kagaku
Co. Ltd, Tokyo, Japan). Individuals with antibody concentration <10
U/ml were categorized as the H. pylori infection-negative group
according to the manufacturer’s recommended cutoff value, and this
cutoff value has been widely used in previous studies (5, 16, 22, 27).
The reported sensitivity and specificity of this kit using the cutoff
value were 91.2% and 97.4%, respectively, based on the results of
stool antigen test as gold standard (28), and other investigators
reported sensitivity of 100% and specificity of 80%, using rapid
urease test, culture and histology as a gold standard (29). 
Exclusion criteria were as follows: i) use of histamine-2 receptor
antagonists or proton pump inhibitors within the preceding two
months; ii) H. pylori eradication therapy before the study as recalled
by the patient; iii) presence of viral diseases such as acute
respiratory diseases; iv) pregnancy or lactation; or v) a history of
severe renal or liver dysfunction. 
Gastrointestinal endoscopy was performed using electrical
panendoscopes (type XQ260; Olympus, Tokyo, Japan). All
endoscopies were performed by a single experienced gastroenterologist
(HK). Gastric neoplasia was defined as gastric cancer and adenoma.
All gastric neoplasias were treated endoscopically or surgically, and
specimens obtained were fixed with buffered formalin and stained with
hematoxylin and eosin. Pathologic diagnoses were reviewed by
experienced pathologist (JM) and judged according to the criteria of
the Japanese Classification of Gastric Carcinoma (30). Endoscopic
gastric mucosal atrophy was diagnosed by an endoscopic scoring
system using the endoscopic atrophic border of Kimura and Takemoto
and the extent of atrophy was divided into normal and open type or
closed type (31).
This study was approved by the Tokyo Dental College Ichikawa
General Hospital Ethics Committee (No. 101-B/2007, 283/2012 and
I-283R/2015) and was conducted according to the principles of the
Second Declaration of Helsinki. All patients provided their written,
informed consent prior to enrollment.
Statistical analysis. Statistical analysis was performed with the
Statistical Package for the Social Sciences (SPSS) v. 22 (SPSS Inc.,
Chicago, IL, USA) for Windows. Data are expressed as
means±standard deviation (SD). Comparisons between groups were
performed using the t-test for continuous variables and the chi-
square test and Fisher’s exact test for categorical variables to
compare gastric neoplasia cases and no-gastric neoplasia cases. 
Factors associated with gastric neoplasia cases were then
evaluated using receiver operating characteristic curves (ROC), and
area under the receiver operating characteristic curve (AUROC)
analysis was used to assess the utility and the goodness-of-fitness
of parameters in the diagnosis of gastric neoplasia in group A.
Comparison of ROC curves was obtained using the Hanley-McNeil
method. Using significant factors, univariate and multiple logistic
regression analyses were performed. A two sided p-value of less
than 0.05 was considered significant.
Results
Study participants. Figure 1 shows the exclusion process for
identifying individuals with a negative H. pylori status (<10
U/ml) and a negative pepsinogen test (atrophy-negative:
pepsinogen-I >70 ng/ml, or pepsinogen-I/II ratio >3). After
excluding those who met the exclusion criteria, a total of 734
individuals, including 43 gastric neoplasia cases, were enrolled
in our study, and 357 with a positive H. pylori antibody titer
(≥10 U/ml; groups B and C), and 32 pepsinogen test-positive
and H. pylori-negative with extensive atrophic gastritis
(pepsinogen-I ≤70 ng/ml, pepsinogen-I/II ratio ≤3 and H.
pylori antibody titer <10 U/ml; group D) were excluded.
Consequently, 193 (26.1%) were classified as group B, 164
(23.2%) as group C, and 32 (3.7%) as group D, according to
the ABC method. Finally, 345 patients (47.1%) were included
for the final analysis and diagnosed as belonging to group A.
Baseline characteristics and comparisons between H. pylori-
negative individuals with low and high antibody titers. Table
I shows the baseline characteristics of the study subjects. A
total of 345 individuals (170 men ( 49.3%), mean age
57.7±15.2 years) were examined for the study. The reasons
for endoscopic examination were dyspepsia in 202 patients,
annual endoscopic follow-up in 48, screening purpose in 25,
abnormalities on barium X-ray examinations in 65, and
positive result for ABC screening method in five. The mean
pepsinogen-I concentration was 50.4±22.3 ng/ml, and the
mean pepsinogen-I/II ratio was 6.8±1.8. 
These various parameters were compared between cases
with gastric neoplasia and those without. The mean age and
the H. pylori antibody titer were significantly lower in the
cases without gastric neoplasia than in gastric neoplasia
cases (p<0.01). The mean pepsinogen-I/II ratio (p<0.01) was
significantly higher in cases without gastric neoplasia.
However, there were no significant differences in
pepsinogen-I levels. The prevalence of endoscopically
atrophic cases (both of closed type and open type) was
significantly higher in those with gastric neoplasia (10/10)
than in those without (57/335).
Table I also shows the clinical characteristics of 10 cases of
H. pylori- and atrophy-negative gastric neoplasia. Four patients
underwent endoscopy for dyspepsia, three for abnormal
barium-X ray result, two for annual health check-up, and one
due to positive ABC screening method. Thus, six
asymptomatic cases and four dyspeptic cases are included.
Eight patients were men. Histologically, eight out of the 10
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had well-differentiated adenocarcinoma, one had poorly
differentiated adenocarcinoma, and one had gastric adenoma.
In seven cases, the depth of invasion was confined to the
mucosa, and in three cases it was at the submucosal layer or
deeper. Seven cases were resected endoscopically, and three
underwent curative surgery. 
Assessment of the predictive accuracy for gastric neoplasia
cases in group A. ROC analysis was performed to evaluate
screening utility and identify a cutoff point for H. pylori
antibody titer, pepsinogen-I/II ratio, and age, which were
significantly different between gastric neoplasia cases and cases
without gastric neoplasia. These three factors were all
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Figure 1. Study flow diagram.
Table I. Baseline study population characteristics with and without gasric neoplasia.
Characteristic All, N=345 Gastric neoplasia N=10 No gastric neoplasia N=335 p-Value
Male (N%) 170 (49.3%) 8 (80.0%) 162 (48.4%) 0.06
Age (years, mean±SD) 57.7±15.2 70.9±6.4 57.3±15.2 <0.01*
Pepsinogen I (ng/ml, mean±SD) 50.4±22.3 37.6±19.3 50.8±22.3 0.06
Pepsinogen I/II ratio (mean±SD) 6.8±1.8 4.9±1.4 6.8±1.7 <0.01*
H. pylori antibody titer (U/ml, mean±SD) 0.7±1.9 4.3±3.1 0.6±1.7 <0.01*
Endoscopic atrophic border 67/345 0/10 57/335 <0.01*
(normal/close type or open type)
Pathology
Adenoma/intestinal/diffuse 1/8/1
Deapth of invasion
M/SM-MP 7/3
Treatment
ESD or EMR/Surgery 7/3
*A p-value of less than 0.05 was considered significant in the comparison between cases with gastric neoplasia and those without. Intestinal:
intestinal-type, diffuse: diffuse-type gastric cancer according to the Japanese Classification of the Gastric Cancer. M: Mucosa, SM: submucosa, and
MP: muscularis mucosa, ESD: endoscopic submucosal dissection, EMR: endoscopic mucosal resection.
significant for predicting gastric neoplasia. The AUROC for H.
pylori antibody titer in predicting gastric neoplasia in group A
was 0.846±0.08 [95% confidence interval (CI)=0.698-0.993,
p<0.01; cutoff value=1.5 U/ml, sensitivity=80%,
specificity=87.5%]. The AUROC for the pepsinogen-I/II ratio
was 0.809±0.07 (95% CI=0.673-0.945, p<0.01; cutoff
value=4.35, sensitivity=60%, specificity=95.5%), and that of
age was 0.774±0.06 (95% CI=0.664-0.883, p<0.01; cutoff
value=70.5 years, sensitivity=60%, specificity=79.1%). To set
the cutoff value of H. pylori antibody titer to 1.5 U/ml is
equivalent to lowering the cutoff value from 10 U/ml to 3 U/ml
because results greater than 0 U/ml are expressed continuously
from 3 to 100 U/ml. Thus, practically, a high antibody titer for
those who were H. pylori-negative (≥3 U/ml), a low
pepsinogen-I/II ratio (≤4.3), and older age (≥71 years) were
associated with gastric neoplasia cases on the ROC analysis. 
Factors associated with gastric neoplasia on univariate and
multivariate logistic regression analyses. To further explore
the associations with gastric neoplasia cases in group A,
univariate and multivariate logistic regression analyses
incorporating H. pylori antibody titer (≥3 U/ml or not),
pepsinogen-I/II ratio (≤4.3 or not), and age (≥71 year or not)
were performed (Table II). Univariate analysis revealed that
H. pylori-negative antibody titer ≥3 U/ml (p<0.001),
pepsinogen-I/II ratio ≤4.3 (p<0.001) and age ≥71 years
(p<0.001) as predictors of gastric neoplasia in group A. We
performed multivariate logistic regression analysis using
these three variables. The evaluation including serum H.
pylori antibody titer and pepsinogen-I/II ratio showed that
these two factors retained an independent association with
gastric neoplasia cases (model 1). In model 2 incorporating
age and pepsinogen-I/II ratio, age did not show any
significant trend towards association with gastric neoplasia.
Logistic regression analysis incorporating these three factors
indicated that serum H. pylori antibody titer [odds ratio
(OR)=14.4, 95% CI=2.7-76.9, p<0.0 1] and pepsinogen-I/II
ratio (OR=10.0, 95% CI: 2.1-47.9; p<0.01) were
independent predictors, however, age did not show any
significant association. In model 2 and model 3, age lost
significant association with gastric neoplasia. Thus, serum
H. pylori antibody titer and pepsinogen-I/II ratio,
independently predicted gastric neoplasia, and the AUROC
of model 1 was statistically better than that of both model 2
and 3 (Table III). 
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Table II. Univariate and multivariate analyses to identify potential risk factors for gastric neoplasia in subjects negative for Helicobacter pylori
antibody and with normal pepsinogen levels.
No. (%) of Gastric neoplasia OR (95% CI)
individuals prevalence
Univariate Multivariate
Model 1 Model 2 Model 3
H. pylori antibody titer (U/ml)
≥3 51 (14.8%) 8/51 (15.7%) 27.1 (5.6-132.2) 14.9 (2.80-79.4) 14.4 (2.7 -76.9)
<3 294 (85.2%) 2/294 (0.7%) 1 1 1
p-Value <0.001* <0.01* <0.01*
Pepsinogen I/II ratio 
≤4.3 22 (6.4%) 6/22 (27.3%) 29.9 (7.7-116.7) 13.3 (3.0-59.1) 21.2(5.0-90.5) 10.0 (2.1-47.9)
>4.3 323 (93.6%) 4/323 (1.2%) 1 1 1 1
p-Value <0.001* <0.01* <0.01* <0.01*
Age (years)
≥71 76 (22.0%) 6/76 (7.9%) 5.7 (1.6-20.7) 2.6 (0.6-11.1) 2.3 (0.5 -10.9)
<71 269 (78.0%) 4/269 (1.5%) 1 1 1
p-Value <0.001* 0.203 0.279
*A p-value less than 0.05 was considered significant. Model 1 includes logistic regression analysis for H. pylori antibody titer and pepsinogen-I/II
ratio as predictors of gastric neoplasia cases. Model 2 incorporates age and pepsinogen-I/II ratio. Model 3 includes all three variables. In Model 2
and Model 3, age did not have any statistically significant association with gastric neoplasia.  OR: Odds ratio; CI: confidence interval.
Table III. Assessment of the fit of multivariate analysis models.
AUROC Standard p-Value 95% Confidence 
Error interval
Model 1 0.872 0.056 <0.01‡ 0.762-0.983
Model 2 0.734* 0.085 <0.05‡ 0.567-0.900
Model 3 0.792** 0.06 <0.01‡ 0.674-0.910
AUROC: Area under the receiver operating characteristic curve;
*p<0.05 vs. Model 1. **p<0.01 vs. Model 1. ‡A p-value less than 0.05
was considered significant. 
Discussion
Although barium radiography has been the most common
gastric cancer screening method in Japan, the ABC method is
now widely incorporated into the gastric cancer screening
program in Japan (12, 14, 32, 33). 
In the present study, H. pylori infection was determined by
a commonly used direct EIA kit based on H. pylori strains
from Japanese individuals. This EIA kit using 10 U/ml as a
cutoff value has been widely applied to large studies
analyzing over 1,000 participants (5, 22, 27, 34), and the
accuracy of this kit to detect current H. pylori infection has
been well established. However, in the present study, it was
found that even within the normal range for H. pylori-
negative individuals, a relatively high serum H. pylori
antibody titer (≥3 U/ml) is useful for detecting gastric
neoplasia in individuals classed as group A by ABC, in which
endoscopy is not usually recommended. 
Considering that more than 99% of gastric cancer cases
are associated with H. pylori infection (2, 5), gastric
neoplasia cases in group A are not considered 'true-negative'
H. pylori cases but as cases with past infection. We consider
that the development of gastric neoplasia in group A may
possibly be related to the gastric mucosa after unexpected
eradication of H. pylori. Use of antibiotics has increased
significantly, and such increased use of antibiotics may also
induce unexpected eradication of H. pylori globally (35).
Although a significant decrease in the antibody titer occurs
after eradication, seroreversion 18 months after eradication
is reported to occur in as many as 45% (36, 37). Thus,
complete seronegativity cannot usually be obtained even
after successful eradication therapy. We hypothesized that in
spontaneously eradicated cases, the antibody titer decreased
significantly but did not actually reach zero, which is why
lowering the cutoff value of the antibody titer is effective for
detecting neoplasia in group A.
We also clarified that a low pepsinogen-I/II ratio (≤4.3) is
useful for detecting gastric neoplasia in group A.
Characteristically, because of the increase in the pepsinogen-
I/II ratio after successful eradication therapy (38, 39), most
cases with atrophic pepsinogen (typically pepsinogen-I/II
ratio <3.0) are classified as 'seemingly normal pepsinogen'
after eradication therapy but the pepsinogen-I/II ratio usually
does not achieve high values. Thus, low-normal pepsinogen-
I/II ratios in group A may represent advanced atrophy after
eradication. The present finding that a pepsinogen-I/II ratio
of 4.3 or less is associated with gastric neoplasia suggests
that these cases were originally of advanced atrophy and
should be regarded as high-risk.
In the present study a population of 734 individuals with
43 cases of gastric neoplasia, 389 (53.0%) were classified
into groups B-D, including 33 of gastric neoplasia, who
required further examination by endoscopy; suggesting that
33 out of 43 (76.7%) cases became candidates for
endoscopic examination. If individuals with an H. pylori
antibody titer ≤3 U/ml or a pepsinogen-I/II ratio ≤4.3 are
regarded as 'positive' in group A, candidates for further
endoscopic examination increased significantly from
76.7% (33 out of 43) to 97.7% (42 out of 43 gastric
neoplasia cases). 
The prevalence of gastric neoplasia cases (2.9 %) among
group A individuals in this study is higher than that of
previous studies (14, 40). One possible reason for this high
prevalence is that our study population included
symptomatic cases and abnormal barium X ray cases,
although the study subjects of previous reports were based
on asymptomatic individuals undergoing a health checkup.
This finding suggests that high-risk gastric neoplasia cases
may be included in group A if the ABC method is applied
to outpatients. However, because the serological
characteristics of asymptomatic group A cases and those of
outpatient cases are nearly identical (pepsinogen I/II ratio
in asymptomatic cases and our outpatients was 3.6 and 3.8,
respectively), we consider that this cutoff point is
applicable to both these groups (40). Because the ABC
method is a non-invasive method for stratifying the risk of
future gastric carcinogenesis, we consider that it can be
adapted to screening asymptomatic individuals as well as
outpatient cases.
Several limitations should be considered when interpreting
the results of this study. Firstly, there were only 10 gastric
neoplasia cases in group A in this study, and it is important
to further clarify the risk factors for gastric neoplasia in
group A in a larger, multi-institutional study. The second is
the validity of dividing individuals with 'negative' antibody
titer into two sub-groups. However, the cutoff value to detect
those with current as well as past infection should be
established to identify those at high risk of gastric cancer in
group A. We have demonstrated that in group A, an antibody
titer lower than the recommended cutoff value has important
meaning for the identification of those at high risk,
suggesting that lowering the cutoff value can be justified in
this limited population. 
In conclusion, two predictors, a high H. pylori-negative
antibody titer (≥3 U/ml) and a low pepsinogen-I/II ratio
(≤4.3) are important factors for effectively detecting
neoplasia in cases classed as group A by the ABC method.
Since group A is usually regarded as consisting of
individuals with a healthy stomach, the identification of
high-risk cases in group A is an urgent problem. Thus, we
consider that the present findings are especially important in
countries using the ABC method for gastric cancer screening.
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